The big data challenge-and how polypharmacology supports the translation from pre-clinical research into clinical use against neurodegenerative diseases and beyond
Sven Marcel Stefan1
Muhammad Rafehi2
1.Drug Development and Chemical Biology,Lübeck Institute of Experimental Dermatology(LIED),University of Lübeck and University Medical Center Schleswig-Holstein,Lübeck,Germany;Department of Pathology,Section of Neuropathology,Translational Neurodegeneration Research and Neuropathology Lab,University of Oslo and Oslo University Hospital,Oslo,Norway;School of Medical Sciences,Faculty of Medicine and Health,University of Sydney,Sydney,NSW,Australia2.Institute of Clinical Pharmacology,University Medical Center Göttingen,Göttingen,Germany;Department of Medical Education,Augsburg University Medicine,Augsburg,Germany
摘要：Introductory comments:The identification and validation of disease-modifying proteins are fundamental aspects in drug development.However,the multifactority of neurodegenerative diseases poses a real challenge for targeted therapies.Furthermore,the behavior of individually(over-)expressed target proteins in vitro is likely to differ from their actual functional behavior when embedded in cascades and pathways in vivo.Increased compartmentalization,e.g.,in the brain,adds to the complexity.
机标关键词：researchneurodbeyonddatafromagainstchallenge-anddegenerative
论文发表日期：2024-08-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：2( 1647-1648 )